Biological effective dose as a predictor of local tumor control in stereotactic radiosurgery treated parasellar meningioma patients.

IF 3.1 2区 医学 Q2 CLINICAL NEUROLOGY Journal of Neuro-Oncology Pub Date : 2024-11-01 Epub Date: 2024-08-27 DOI:10.1007/s11060-024-04804-1
Ahmed Shaaban, Duy Pham, Salem M Tos, Georgios Mantziaris, David Schlesinger, Jason P Sheehan
{"title":"Biological effective dose as a predictor of local tumor control in stereotactic radiosurgery treated parasellar meningioma patients.","authors":"Ahmed Shaaban, Duy Pham, Salem M Tos, Georgios Mantziaris, David Schlesinger, Jason P Sheehan","doi":"10.1007/s11060-024-04804-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The radio-surgical literature increasingly uses biological effective dose (BED) as a replacement for absorbed dose to analyze outcome of stereotactic radiosurgery (SRS). There are as yet no studies which specifically investigate the association of BED to local tumor control in para-sellar meningioma.</p><p><strong>Methods: </strong>we did a retrospective analysis of patients underwent stereotactic radiosurgery (SRS) for para-sellar meningioma during the period of 1995-2022. Demographic, clinical, SRS parameters, and outcome data were collected. The target margin BED with and without a model for sub-lethal repair was calculated, as well as a ratio of BED at the target margin to the absorbed dose at the target margin. Factors related to local control were further analyzed.</p><p><strong>Results: </strong>The study was comprised of 91 patients, 20 (22.0%) and 71 (78.0%) of whom were male and female, respectively. The median age was 55.0 (interquartile range Q1, Q3:47.5,65.5years). 34 (37%) patients had a resection of their meningioma prior to SRS. The median interval from SRS to last clinical follow up or progression was 89 months. 13 (14.3%) patients were found to have progression. 3-, 5- and 10-years local tumor control were 98%, 92% and 77%, respectively. In cox univariate analysis, the following factors were significant: Number of prior surgical resections (Hazard Ratio [HR] = 1.82, 95% CI = 1.08-3.05, p = 0.024), BED (HR = 0.96, 95% CI = 0.92-1.00, p = 0.03), and BED/margin (HR = 0.44, 95% CI = 0.21-0.92, p = 0.028). A BED threshold above 68 Gy was associated significantly with tumor control (P = 0.04).</p><p><strong>Conclusion: </strong>BED and BED /margin absorbed dose ratio can be predictors of local control after SRS in parasellar meningioma. Optimizing the BED above 68Gy<sub>2.47</sub> may afford better long-term tumor control.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"377-385"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538185/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-024-04804-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The radio-surgical literature increasingly uses biological effective dose (BED) as a replacement for absorbed dose to analyze outcome of stereotactic radiosurgery (SRS). There are as yet no studies which specifically investigate the association of BED to local tumor control in para-sellar meningioma.

Methods: we did a retrospective analysis of patients underwent stereotactic radiosurgery (SRS) for para-sellar meningioma during the period of 1995-2022. Demographic, clinical, SRS parameters, and outcome data were collected. The target margin BED with and without a model for sub-lethal repair was calculated, as well as a ratio of BED at the target margin to the absorbed dose at the target margin. Factors related to local control were further analyzed.

Results: The study was comprised of 91 patients, 20 (22.0%) and 71 (78.0%) of whom were male and female, respectively. The median age was 55.0 (interquartile range Q1, Q3:47.5,65.5years). 34 (37%) patients had a resection of their meningioma prior to SRS. The median interval from SRS to last clinical follow up or progression was 89 months. 13 (14.3%) patients were found to have progression. 3-, 5- and 10-years local tumor control were 98%, 92% and 77%, respectively. In cox univariate analysis, the following factors were significant: Number of prior surgical resections (Hazard Ratio [HR] = 1.82, 95% CI = 1.08-3.05, p = 0.024), BED (HR = 0.96, 95% CI = 0.92-1.00, p = 0.03), and BED/margin (HR = 0.44, 95% CI = 0.21-0.92, p = 0.028). A BED threshold above 68 Gy was associated significantly with tumor control (P = 0.04).

Conclusion: BED and BED /margin absorbed dose ratio can be predictors of local control after SRS in parasellar meningioma. Optimizing the BED above 68Gy2.47 may afford better long-term tumor control.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
生物有效剂量作为立体定向放射外科治疗髌旁脑膜瘤患者局部肿瘤控制的预测指标。
简介:放射外科文献越来越多地使用生物有效剂量(BED)代替吸收剂量来分析立体定向放射手术(SRS)的结果。方法:我们对 1995-2022 年间接受立体定向放射外科手术(SRS)治疗星旁脑膜瘤的患者进行了回顾性分析。收集了人口统计学、临床、SRS参数和结果数据。计算了有亚致死修复模型和无亚致死修复模型的靶边缘BED,以及靶边缘BED与靶边缘吸收剂量的比值。研究还进一步分析了与局部控制有关的因素:该研究由 91 名患者组成,其中男性和女性患者分别为 20 人(22.0%)和 71 人(78.0%)。中位年龄为 55.0 岁(四分位数范围 Q1、Q3:47.5、65.5 岁)。34名(37%)患者在接受SRS治疗前切除了脑膜瘤。从SRS到最后一次临床随访或病情进展的中位间隔为89个月。13例(14.3%)患者的病情有所进展。3年、5年和10年的局部肿瘤控制率分别为98%、92%和77%。在 cox 单变量分析中,以下因素具有显著性:既往手术切除次数(危险比 [HR] = 1.82,95% CI = 1.08-3.05,p = 0.024)、BED(HR = 0.96,95% CI = 0.92-1.00,p = 0.03)和 BED/边缘(HR = 0.44,95% CI = 0.21-0.92,p = 0.028)。BED阈值高于68 Gy与肿瘤控制显著相关(P = 0.04):结论:BED和BED/边缘吸收剂量比可以预测髌旁脑膜瘤SRS术后的局部控制情况。优化 BED,使其高于 68Gy2.47 可获得更好的长期肿瘤控制效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Neuro-Oncology
Journal of Neuro-Oncology 医学-临床神经学
CiteScore
6.60
自引率
7.70%
发文量
277
审稿时长
3.3 months
期刊介绍: The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
期刊最新文献
Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy. Advances in imaging modalities and tumor classification for vestibular schwannomas. Incidence of primary central nervous system tumors across age groups and histological groups in Osaka, Japan, 2011-2020. The predictive value of serum neurofilament light chain combined with inflammatory biomarkers for post-surgical epilepsy after brain tumor resection: a retrospective diagnostic study. Clinical durability of junction-terminating CFR-PEEK constructs in oncologic spine surgery: a single-center retrospective analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1